Mabion (WAR:MAB) Total Liabilities: zł70.76 Mil (As of Mar. 2026)


WAR:MAB Mabion SA WAR:MAB
29 GF Score
Price zł7.28
GF Value zł2.09
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Mabion Total Liabilities?

Mabion WAR:MAB -1.62% 29 Total Liabilities is zł70.76 Mil as of Mar. 2026. GuruFocus rates WAR:MAB with a GF Score™ of 29/100 and a GF Value™ of zł2.09 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Mabion's Total Liabilities for the quarter that ended in Mar. 2026 was zł70.76 Mil.

Mabion's quarterly Total Liabilities increased from Sep. 2025 (zł50.44 Mil) to Dec. 2025 (zł61.61 Mil) and increased from Dec. 2025 (zł61.61 Mil) to Mar. 2026 (zł70.76 Mil).

Mabion's annual Total Liabilities declined from Dec. 2023 (zł90.48 Mil) to Dec. 2024 (zł48.03 Mil) but then increased from Dec. 2024 (zł48.03 Mil) to Dec. 2025 (zł61.61 Mil).

Mabion Total Liabilities Historical Data

* Premium members only.

The historical data trend for Mabion's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mabion Total Liabilities Chart

Mabion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 130.92 109.67 90.48 48.03 61.61

Mabion Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.17 47.25 50.44 61.61 70.76
WAR:MAB
29GF Score
Mabion SA WAR:MAB
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mabion Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Mabion's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=43.854+(11.227+6.524
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=61.61

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=110.433-48.828
=61.61

Mabion's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=46.286+(17.998+6.472
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=70.76

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=109.846-39.09
=70.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of zł70.76 Mil mean?
Mabion (WAR:MAB) has a Total Liabilities of zł70.76 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Mabion and its competitors.
Is Mabion's Total Liabilities too high?
Mabion's current Total Liabilities is zł70.76 Mil. Overall, Mabion has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mabion's Total Liabilities compare to VRTX and REGN?
Mabion's Total Liabilities of zł70.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Mabion and its competitors. Mabion's current Total Liabilities is zł70.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabion stock overvalued right now?
Based on GuruFocus' analysis, Mabion (WAR:MAB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł2.09, compared to a current price of zł7.28 — trading 248.3% above its estimated fair value. The current Total Liabilities is zł70.76 Mil. Mabion's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Mabion (WAR:MAB), the current Total Liabilities is zł70.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mabion (WAR:MAB) Overvalued in 2026?

Based on GuruFocus' analysis, Mabion stock appears to be overvalued. The current stock price of zł7.28 is trading 248.3% above its estimated GF Value™ of zł2.09. GuruFocus considers Mabion to be Significantly Overvalued.

Key valuation signals for WAR:MAB:

  • Total Liabilities: zł70.76 Mil
  • GF Value™: zł2.09 vs. price of zł7.28 (248.3% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the WAR:MAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mabion Business Description

Other Exchanges 272:Germany
Address ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
29GF Score

Get the complete analysis for WAR:MAB

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.28
Price
zł2.09
GF Value